Google
OVID — OVID THERAPEUTICS INC (Healthcare >> Biotechnology)
OVID FAQ
What is OVID's P/E ratio?
OVID THERAPEUTICS INC (OVID) currently trades at a P/E ratio of 43.75.
What is OVID's ROE?
OVID THERAPEUTICS INC reports a Return on Equity (ROE) of -12.19%.
What is OVID's dividend yield?
OVID THERAPEUTICS INC offers a dividend yield of 0.00%.
What is OVID's Deepscope Quality Score?
Deepscope rates OVID's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy OVID?
Deepscope's AI Timing Score for OVID is 56 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does OVID belong to?
OVID THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 2.30
Price
0.09
(4.07%)
Day Change
|
|
|---|
OVID, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 93 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 2.30 |
| PBV / Sector |
2.13 / 4.91
|
| Earning Per Share | -0.13 |
| PE / Sector |
43.75 / 18.34
|
| PEG or PE/Growth / Sector |
-1.55 / 0.61
|
| Average 1M Daily Value |
3.69 M
GREAT
|
| Average 1W Daily Value |
4.37 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
60% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-13 11:13:50 |
| Symbol | OVID |
| Name | OVID THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 186.64 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 422.74 / 9,034.83 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Hudson Commons, New York, NY, United States, 10001
Phone: 646 661 7661
Website: https://www.ovidrx.com
Sector: Healthcare >> Biotechnology
Description: Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
